Key Takeaways
- Distillate Capital Partners, which manages $2.11 billion, added to UnitedHealth, Booking Holdings and T-Mobile US in the third quarter, its latest 13F shows.
- Analysts’ average price targets are 37% to 48% above the last close for all three.
- UnitedHealth’s average target and its 2027 earnings estimate have both risen in recent months. Booking’s and T-Mobile’s targets have fallen.
- The numbers back UnitedHealth best of the three, but a proposed Medicare Advantage audit rule is the risk to watch.
If you’re hunting for big-name stocks that have fallen out of favor, a mid-sized fund just handed you a short list. Distillate Capital Partners, which manages $2.11 billion, added to UnitedHealth (UNH), Booking Holdings (BKNG) and T-Mobile US (TMUS) in the third quarter. That’s what its 13F for the quarter ended Sept. 30, filed Nov. 16, shows. They were the three biggest of its six new or added positions, in a 13F that holds $2.10 billion of US stocks across 117 names.
UnitedHealth got the biggest boost
Distillate ended September with 114,479 UnitedHealth shares, 84% more than three months earlier. The $42 million stake was 2.0% of its 13F stocks, making it the fund’s No. 3 holding. The stock is down 7% since the quarter ended. It sank when CMS proposed a rule on Nov. 16 that would apply Medicare Advantage audit findings to whole contracts and claw back overpayments as far back as payment year 2018. CMS expects to recover about $9 billion a payment year across the industry, and UnitedHealth hasn’t said how much of that would be its share.
Analysts haven’t backed off. Their average target has climbed from $389 a year ago to $478, close to September’s high of $482:

That’s 41% above the last close of $339.85. Consensus 2027 adjusted EPS has risen to $23.33 from $20.93 at the end of June. TD Cowen upgraded the stock to Buy on Nov. 20, lifting its target to $455 from $402. At about 15x forward earnings, UnitedHealth trades well below its five-year average of 20x.
TIKR tracks 26 analysts on UnitedHealth. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on UnitedHealth, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See UnitedHealth’s Analyst Ratings
Booking’s targets keep falling
Analysts see Booking very differently. Distillate raised its stake 28% to 218,525 shares, worth $36 million at Sept. 30. That’s 1.7% of its 13F stocks and its No. 8 holding. The stock is down 11% since then and is 34% below its 52-week high. Analysts have cut their average target all year, from $248 a year ago to $215, its lowest of the year:

The stock fell faster, from $183 to $144.91, so the upside to the average target has widened to 48% even as analysts have grown less sure. The lowest target on the Street dropped to $150 in early November, barely above the last close. At about 12x forward earnings, Booking looks cheap, but analysts are still cutting their targets.
T-Mobile has held up best
T-Mobile is the only one of the three that’s up since Sept. 30, by 2%. Distillate added 22% to its stake, ending the quarter with 194,723 shares worth $32 million. That’s 2% of its 13F stocks and its No. 10 holding. The stock is still 26% below its 52-week high, and a new rival may be coming: SpaceX is reportedly in talks to buy Boost Mobile, which could give it the reach to compete in wireless. Analysts have cut their average target from $275 a year ago to $226, near its low for the year:

That still leaves 37% upside, and the stock trades at about 12x forward earnings.
UnitedHealth is the one I’d follow
Wall Street sees big upside in all three, but only UnitedHealth has analysts raising their numbers while the stock falls. Booking’s low multiple comes with targets that haven’t stopped dropping, and T-Mobile may soon face a new competitor with deep pockets. So my pick of the three is UnitedHealth: analysts keep raising their estimates, and the price hasn’t caught up.
The risk is Washington. CMS’s audit rule is open for comment until Jan. 19. And with Democrats now in control of Congress, Sen. Elizabeth Warren has called for breaking up UnitedHealth, CVS Health and Cigna. UnitedHealth has promised its 2027 outlook before year-end. An adjusted EPS guide at or above the $23.33 consensus would back Distillate’s bet. Just keep in mind that a 13F only shows what the fund held on Sept. 30, and its next one is due by mid-February.
So what is UnitedHealth stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what UnitedHealth could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!